<DOC>
	<DOCNO>NCT00526513</DOCNO>
	<brief_summary>Primary Objectives : To determine effect insulin glulisine glycemic control ( HbA1c , FBG &amp; PPBG ) baseline end study . Secondary Objectives : To evaluate safety insulin glulisine basal/bolus regimen monitor incidence hypoglycemia adverse event .</brief_summary>
	<brief_title>Study Safety Effectiveness ApidraÂ® Combination With Basal Insulin Patients With Type 1 &amp; 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Patients type 1 type 2 diabetes mellitus previously treat 6 month prandial insulin + Basal insulin Premix ( Type I ) either basal insulin + OAD basal + RHI/other short act analogue insulin Premix ( Type II ) HbA1c &gt; 7 % . Adequate hepatic renal function Ability willingness tight antidiabetic therapy perform blood glucose selfmonitoring especially blood glucose profile , use blood glucometer home . Pregnant lactate woman woman childbearing potential use adequate contraception . Patients hypersensitivity insulin glulisine excipients . History diabetic ketoacidosis . Diabetic retinopathy surgical treatment ( laser photocoagulation vitrectomy ) 3 month prior study entry may require surgical treatment within 3 month study entry . Alcohol abuse drug abuse . Clinically relevant cardiovascular , gastrointestinal , hepatic , neurological , endocrine , hematological psychiatric illness , serious illness , uncontrolled medical condition active infection make implementation protocol difficult . Medical , psychiatric , neurologic condition render patient unable understand nature scope study . Mental retardation language barrier patient unable give inform consent . Participation investigational trial within 30 day study entry . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>